破伤风类毒素、白喉类毒素及交叉反应物质197（CRM197）用作糖缀合物载体蛋白时的潜在保护性免疫原性。
Potential protective immunogenicity of tetanus toxoid, diphtheria toxoid and Cross Reacting Material 197 (CRM197) when used as carrier proteins in glycoconjugates.
作者信息
Bröker Michael
机构信息
a GSK Vaccines GmbH , Marburg , Germany.
出版信息
Hum Vaccin Immunother. 2016 Mar 3;12(3):664-7. doi: 10.1080/21645515.2015.1086048.
Abstract
When tetanus toxoid (TT), diphtheria toxoid (DT) or Cross Reacting Material 197 (CRM197), a non-toxic diphtheria toxin mutant protein, are used as carrier proteins in glycoconjugate vaccines, these carriers induce a protein specific antibody response as measured by in vitro assays. Here, it was evaluated whether or not glycoconjugates based on TT, DT or CRM197 can induce a protective immune response as measured by potency tests according to the European Pharmacopoeia. It could be shown, that the conjugate carriers TT and DT can induce a protective immune response against a lethal challenge by toxins in animals, while glycoconjugates based on CRM197 failed to induce a protective immune response. Opportunities for new applications of glycoconjugates are discussed.
摘要
当破伤风类毒素（TT）、白喉类毒素（DT）或交叉反应物质197（CRM197，一种无毒的白喉毒素突变蛋白）用作糖缀合物疫苗中的载体蛋白时，这些载体可诱导体外检测所测定的蛋白质特异性抗体反应。在此，根据欧洲药典通过效价试验评估了基于TT、DT或CRM197的糖缀合物是否能诱导保护性免疫反应。结果表明，结合物载体TT和DT可诱导动物产生针对毒素致死性攻击的保护性免疫反应，而基于CRM197的糖缀合物未能诱导保护性免疫反应。文中还讨论了糖缀合物新应用的机会。
相似文献
1
Potential protective immunogenicity of tetanus toxoid, diphtheria toxoid and Cross Reacting Material 197 (CRM197) when used as carrier proteins in glycoconjugates.破伤风类毒素、白喉类毒素及交叉反应物质197（CRM197）用作糖缀合物载体蛋白时的潜在保护性免疫原性。
Hum Vaccin Immunother. 2016 Mar 3;12(3):664-7. doi: 10.1080/21645515.2015.1086048.
2
Carrier priming with CRM 197 or diphtheria toxoid has a different impact on the immunogenicity of the respective glycoconjugates: biophysical and immunochemical interpretation.CRM197 或白喉类毒素载体预致敏对相应糖结合物的免疫原性有不同影响：生物物理和免疫化学解释。
Vaccine. 2015 Jan 3;33(2):314-20. doi: 10.1016/j.vaccine.2014.11.026. Epub 2014 Nov 22.
3
Carrier priming effect of CRM197 is related to an enhanced B and T cell activation in meningococcal serogroup A conjugate vaccination. Immunological comparison between CRM197 and diphtheria toxoid.CRM197的载体启动效应与A群脑膜炎球菌结合疫苗接种中B细胞和T细胞的激活增强有关。CRM197与白喉类毒素的免疫学比较。
Vaccine. 2016 Apr 29;34(20):2334-41. doi: 10.1016/j.vaccine.2016.03.055. Epub 2016 Mar 23.
4
Comparison of CRM197, diphtheria toxoid and tetanus toxoid as protein carriers for meningococcal glycoconjugate vaccines.CRM197、白喉类毒素和破伤风类毒素作为脑膜炎球菌糖结合疫苗的蛋白载体的比较。
Vaccine. 2013 Oct 1;31(42):4827-33. doi: 10.1016/j.vaccine.2013.07.078. Epub 2013 Aug 17.
5
Quality, immunogenicity and stability of meningococcal serogroup ACWY-CRM, DT and TT glycoconjugate vaccines.A、C、W、Y群脑膜炎球菌-CRM、DT和TT糖共轭疫苗的质量、免疫原性及稳定性
Vaccine. 2017 Jun 16;35(28):3598-3606. doi: 10.1016/j.vaccine.2017.03.066. Epub 2017 Apr 10.
6
Glycoconjugate vaccines and immune interference: A review.糖缀合物疫苗与免疫干扰：综述。
Vaccine. 2010 Aug 2;28(34):5513-23. doi: 10.1016/j.vaccine.2010.06.026. Epub 2010 Jun 25.
7
Polysaccharide conjugate vaccine protein carriers as a "neglected valency" - Potential and limitations.多糖结合疫苗蛋白载体作为“被忽视的价态”——潜力与局限
Vaccine. 2017 Jun 5;35(25):3286-3294. doi: 10.1016/j.vaccine.2017.04.078. Epub 2017 May 6.
8
9
10
Booster response to the tetanus and diphtheria toxoid carriers of 11-valent pneumococcal conjugate vaccine in adults and toddlers.11价肺炎球菌结合疫苗破伤风和白喉类毒素载体在成人和幼儿中的加强免疫反应。
Vaccine. 2001 Nov 12;20(3-4):336-41. doi: 10.1016/s0264-410x(01)00375-9.
引用本文的文献
1
Typhoid Conjugate Vaccine: A Boon for Endemic Regions.伤寒结合疫苗：流行地区的福音。
Cureus. 2024 Mar 19;16(3):e56454. doi: 10.7759/cureus.56454. eCollection 2024 Mar.
2
Potential Protectivity of a Conjugated COVID-19 Vaccine against Tetanus.一种新冠病毒结合疫苗对破伤风的潜在保护作用。
Vaccines (Basel). 2024 Feb 26;12(3):243. doi: 10.3390/vaccines12030243.
3
Testing a Recombinant Form of Tetanus Toxoid as a Carrier Protein for Glycoconjugate Vaccines.测试破伤风类毒素的重组形式作为糖共轭疫苗的载体蛋白。
Vaccines (Basel). 2023 Nov 28;11(12):1770. doi: 10.3390/vaccines11121770.
4
Immune responses against group B monovalent and pentavalent capsular polysaccharide tetanus toxoid conjugate vaccines in Balb/c mice.Balb/c小鼠对B群单价和五价荚膜多糖破伤风类毒素结合疫苗的免疫反应。
iScience. 2023 Jul 13;26(8):107380. doi: 10.1016/j.isci.2023.107380. eCollection 2023 Aug 18.
5
Synthetic Glycans to Improve Current Glycoconjugate Vaccines and Fight Antimicrobial Resistance.合成糖以改进现有糖缀合物疫苗并对抗抗微生物药物耐药性。
Chem Rev. 2022 Oct 26;122(20):15672-15716. doi: 10.1021/acs.chemrev.2c00021. Epub 2022 May 24.
6
A Mouse Immunogenicity Model for the Evaluation of Meningococcal Conjugate Vaccines.用于评估脑膜炎球菌结合疫苗的小鼠免疫原性模型。
Front Immunol. 2022 Jan 20;13:814088. doi: 10.3389/fimmu.2022.814088. eCollection 2022.
7
A Capsule-Conjugate Vaccine Protects From Experimental Oral Bone Loss.一种胶囊结合疫苗可预防实验性口腔骨质流失。
Front Oral Health. 2021 Jul 5;2:686402. doi: 10.3389/froh.2021.686402. eCollection 2021.
8
A Vaccine Against Group B : Recent Advances.一种针对B族的疫苗：最新进展
Infect Drug Resist. 2020 Apr 29;13:1263-1272. doi: 10.2147/IDR.S203454. eCollection 2020.
9
Incidence of Tetanus and Diphtheria in Relation to Adult Vaccination Schedules.破伤风和白喉的发病率与成人免疫接种计划的关系。
Clin Infect Dis. 2021 Jan 27;72(2):285-292. doi: 10.1093/cid/ciaa017.
10
Application of built-in adjuvants for epitope-based vaccines.基于表位的疫苗中内置佐剂的应用。
PeerJ. 2019 Jan 14;6:e6185. doi: 10.7717/peerj.6185. eCollection 2019.
本文引用的文献
1
Structural correlates of carrier protein recognition in tetanus toxoid-conjugated bacterial polysaccharide vaccines.破伤风类毒素结合细菌多糖疫苗中载体蛋白识别的结构相关性
Vaccine. 2015 Mar 10;33(11):1345-52. doi: 10.1016/j.vaccine.2015.01.046. Epub 2015 Jan 29.
2
Glycoconjugate vaccines: an update.糖缀合物疫苗：最新进展
Expert Opin Biol Ther. 2015 Apr;15(4):529-46. doi: 10.1517/14712598.2015.993375. Epub 2014 Dec 11.
3
Evolving meningococcal immunization strategies.不断发展的脑膜炎球菌免疫策略。
Expert Rev Vaccines. 2015 Apr;14(4):505-17. doi: 10.1586/14760584.2015.979799. Epub 2014 Dec 10.
4
Biochemical and biological characteristics of cross-reacting material 197 CRM197, a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications.交叉反应物质197（CRM197）的生化和生物学特性，一种无毒的白喉毒素突变体：作为疫苗中的偶联蛋白及其他潜在临床应用。
Biologicals. 2011 Jul;39(4):195-204. doi: 10.1016/j.biologicals.2011.05.004. Epub 2011 Jun 28.
Zotero 插件